Neurodegenerative diseases represent a class of fatal brain disorders for which the number of effective therapeutic options remains limited with only symptomatic treatment accessible. Multiple studies show that defects in sphingolipid pathways are shared among different brain disorders including neurodegenerative diseases and may contribute to their complex pathogenesis. In this mini review, we discuss the hypothesis that modulation of sphingolipid metabolism and their related signaling pathways may represent a potential therapeutic approach for those devastating conditions. The plausible "druggability" of sphingolipid pathways is greatly promising and represent a relevant feature that brings real advantage to the development of new therapeutic options for these conditions. Indeed, several molecules that selectively target sphingolipds are already available and many of them currently in clinical trial for human diseases. A deeper understanding of the "sphingolipid scenario" in neurodegenerative disorders would certainly enhance therapeutic perspectives for these conditions, by taking advantage from the already available molecules and by promoting the development of new ones.

Sphingolipid metabolism: A new therapeutic opportunity for brain degenerative disorders / Di Pardo, Alba; Maglione, Vittorio. - In: FRONTIERS IN NEUROSCIENCE. - ISSN 1662-4548. - 12:(2018). [10.3389/fnins.2018.00249]

Sphingolipid metabolism: A new therapeutic opportunity for brain degenerative disorders

Di Pardo, Alba
Primo
Writing – Original Draft Preparation
;
MAGLIONE, VITTORIO
2018

Abstract

Neurodegenerative diseases represent a class of fatal brain disorders for which the number of effective therapeutic options remains limited with only symptomatic treatment accessible. Multiple studies show that defects in sphingolipid pathways are shared among different brain disorders including neurodegenerative diseases and may contribute to their complex pathogenesis. In this mini review, we discuss the hypothesis that modulation of sphingolipid metabolism and their related signaling pathways may represent a potential therapeutic approach for those devastating conditions. The plausible "druggability" of sphingolipid pathways is greatly promising and represent a relevant feature that brings real advantage to the development of new therapeutic options for these conditions. Indeed, several molecules that selectively target sphingolipds are already available and many of them currently in clinical trial for human diseases. A deeper understanding of the "sphingolipid scenario" in neurodegenerative disorders would certainly enhance therapeutic perspectives for these conditions, by taking advantage from the already available molecules and by promoting the development of new ones.
2018
Ceramide; FTY720; Neurodegenerative diseases; S1P; S1PRs; Sphingolipid metabolism; Neuroscience (all)
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Sphingolipid metabolism: A new therapeutic opportunity for brain degenerative disorders / Di Pardo, Alba; Maglione, Vittorio. - In: FRONTIERS IN NEUROSCIENCE. - ISSN 1662-4548. - 12:(2018). [10.3389/fnins.2018.00249]
File allegati a questo prodotto
File Dimensione Formato  
DiPardo_ Sphingolipid_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 415.43 kB
Formato Adobe PDF
415.43 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1208191
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 55
social impact